MedPath

Restrictive vs Goal Directed Fluid Therapy During Hepatobiliary Surgery

Not Applicable
Completed
Conditions
Liver Surgery
Registration Number
NCT04092608
Lead Sponsor
Erasme University Hospital
Brief Summary

"Restrictive" fluid management is usually the current standard practice for patients undergoing liver surgery. The general idea is to maintain a low central venous pressure in order to decrease blood loss and improve the quality of the surgical field. However, this strategy , considered as rather "restrictive", can be associated with patient's harm, mainly acute kidney injury.

Today, Goal directed fluid therapy (GDFT) is a well accepted strategy to optimize fluid administration in patients undergoing major surgery which aimed to maintain normovolemia without being too liberal.

The goal of this randomized controlled trial is to compare these two strategies on Urethral Perfusion index measured with a new IKORUS UP probe (Foley catheter made smarter with embedded photoplethysmographic sensing technology).

Detailed Description

Restrictive fluid administration aiming at maintaining a low central venous pressure (low-CVP) during liver surgery has always been considered as a "gold standard" strategy because it decrease blood loss and improve the quality of the surgical field. However, this strategy , rather "restrictive", can be associated with patient harm (mainly AKI).

Today, Goal directed fluid therapy (GDFT) is a well accepted strategy to optimize fluid administration in patients undergoing major surgery.Some studies have shown that this strategy is feasible for such patient population.

There is currently a lack of data supporting the advantage of one strategy over the other in this patient population.While a restrictive fluid strategy can advantage the surgeon, it can also disadvantage the patient as in order to avoid hypotension, vasopressors administration is required. If the patient is hypovolemic, such strategy may cause acute kidney injury.

The goal of this randomized controlled trial is to compare these two strategies on Urethral Perfusion index measured with a new Foley catheter with embedded photoplethysmographic sensing technology). This new technology allows for continuous and easy monitoring of urethral tissue perfusion

The investigators hypothesis is that patients in the GDFT group will have better Urethral Perfusion index (uPI) during surgery (via a better cardiac blood flow optimization) compared to patients in the restrictive (low CVP) group.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria

-All adults patients undergoing a liver surgery and equipped with a cardiac output monitoring device

Exclusion Criteria

-Atrial fibrillation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Urethral Perfusion indexduring surgery

average of the Urethral Perfusion index values

Secondary Outcome Measures
NameTimeMethod
Stroke volume indexduring surgery

average of stroke volume index during surgery

stroke volume variationduring surgery

average of stroke volume variation during surgery

cardiac indexduring surgery

average of cardiac index during surgery

incidence of acute kidney injuryAt postoperative day 7

incidence of acute kidney injury measured with the KDIGO classification

Urethral Perfusion indexduring surgery

average of the Urethral Perfusion index values during the last 15-30 minutes of the surgery

Amount of vasopressorsduring surgery

amount of vasopressors received during surgery

Amount of fluid during surgeryduring surgery

amount of crystalloid received during the surgery

length of stay in the hospitalPostoperative day 30

length of stay in the hospital

Incidence of postoperative complicationsPostoperative day 30

Incidence of postoperative complications

Trial Locations

Locations (1)

Erasme Hospital

🇧🇪

Brussels, Brussel-hoofdstad, Belgium

Erasme Hospital
🇧🇪Brussels, Brussel-hoofdstad, Belgium

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.